



INNOVAPATH™

**The Premier Journal Bridging
Discovery & Innovation**

Editorial Welcome Packet

San Antonio, TX

March 23, 2025

<https://innovapath.us/index.php/IN/index>

Welcome to the Editorial Team of INNOVAPATH™ (Journal of Translational Medicine & Biotechnology). Our mission is to bridge discovery and clinical impact across translational medicine, pathology, biotechnology, precision medicine, and health-system innovation. INNOVAPATH™ is a peer-reviewed, online-only journal that assigns Crossref DOIs to all articles, maintains a no-fee policy (no APCs or page charges), and is indexed in Google Scholar and Scopus (with Web of Science evaluation in progress). We are committed to rigorous science, transparent reporting, and practical relevance for clinicians, scientists, and policy leaders.

Mission & Scope:

INNOVAPATH™ advances translational medicine, pathology, biotechnology, precision medicine, clinical research, healthcare innovation, and related disciplines that bridge discovery to clinical impact. The journal is peer-reviewed, online-only, assigns DOIs to every article, and operates with a no-fee policy (no APCs, submission, or page charges). Articles are indexed in Google Scholar and Scopus; Web of Science indexing is in progress.

We encourage submissions that are rigorous, ethically sound, and clinically meaningful, including original research, reviews, case reports, technical/methodological work, brief communications, editorials, and letters.

Editorial Structure & Roles:

- Managing Editor: Overall policy, quality, and operations.
- Associate/Section Editors: Manage peer review and make recommendations.
- Editorial Board Members: Review in their expertise, advise on scope and special issues, and promote submissions.
- Guest Editors: Lead themed collections/special issues under board oversight.

Board service is flexible. Typical expectations are 2–6 reviews/year and periodic input on scope, special issues, and policy updates.

Ethics, Integrity & Conflicts:

INNOVAPATH™ aligns with ICMJE and COPE principles: authorship transparency, research ethics, informed consent, animal care, data integrity, and disclosure of conflicts of interest (COI).

Editors and reviewers must recuse themselves from handling manuscripts where a COI exists (recent collaboration, advisor/trainee relationships, financial interests, or competitive positioning). When in doubt, disclose and ask the Managing Editor for a decision.

Peer Review Model & Timelines:

- Review model:
 - Single-blind (reviewers anonymous; authors visible to editors and reviewers). Reviewers must keep all content confidential and may not use manuscript information prior to publication.

- Typical service-level timelines (business days):
 - Initial triage after submission: 3–5 days
 - Reviewer invitations and confirmations: 3–7 days
 - Review period: 14 days (extensions upon request)
 - First decision target: 28–35 days from submission
 - Author revision window: Minor 14–21 days; Major 30–45 days
 - Post-acceptance production (copyedit/typeset/DOI): 7–14 days

Editors should communicate promptly if delays arise and propose a new date.

Workflow (Open Journal Systems or equivalent):

Steps: (1) Submission → (2) Editorial triage → (3) Editor assignment → (4) Reviewer selection and invitations → (5) Reviews received → (6) Decision (accept / minor revision / major revision/reject) → (7) Revision cycle(s) → (8) Final decision → (9) Production (copyediting, proofing, DOI assignment, ORCID update) → (10) Online publication.

Each manuscript has a dashboard with status, deadlines, messages, and files. Use the platform’s templates for invitations and decision letters, or the enclosed versions if you prefer email.

Quality Standards for Reviews:

A high-quality review is constructive, specific, and fair. Please address the following in your review process:

- Novelty/significance;

- Methods and statistics;
- Data availability/reproducibility;
- Ethics/consent;
- Clarity/organization;
- Limitations;
- Concrete recommendations.

Data & Reproducibility:

Encourage authors to: (i) describe methods and statistical analyses in sufficient detail; (ii) share underlying data/code or provide a clear access statement; (iii) register clinical trials or prospective cohorts where applicable; (iv) disclose AI-assisted writing/figure tools, with human oversight declared.

Editors should verify that data availability statements and relevant registrations (e.g., clinicaltrials.gov) are present when required.

Reviewer Recruitment & Diversity:

Build inclusive reviewer pools across geography, gender, career stage, and institution type. Consider early-career reviewers paired with senior co-reviewers, while safeguarding quality and confidentiality.

Communications & Meetings:

We convene editorial calls as needed (typically quarterly) to review metrics, policy updates, and special issues. Between meetings, email is primary; urgent matters can be escalated to the Managing Editor.

Publicity, ORCID & DOIs:

Accepted articles receive a DOI and are discoverable via Google Scholar and Scopus; Web of Science evaluation is in progress. Where authors provide validated ORCID IDs, Crossref metadata allows automatic updates to their ORCID records. The journal maintains a no-publication-fee policy (no APCs or page charges).

Onboarding Checklist (Quick Start)”

- Review Guidance for Reviewers
- Review Ethics/COI Policy
- Join the next editorial call (calendar invite to follow)
- Optional: Suggest two focus topics or a special issue idea

Contacts

Sohail Rao, MD, MA, DPhil
Managing Editor
srao@innovacore.net

Editorial Office:
contact@innovapath.us

Website: <https://innovapath.us>